Product Description
MP1032 is a phase-pure anhydrous polymorph of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt that exhibits good stability and bioavailability.
Mechanisms of Action: Macrophage Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: MetrioPharm AG
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Psoriasis|COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MP1032 Treatment in Patients with Moderate to Severe COVID-19 | P2 |
Completed |
COVID-19 |
2022-07-28 |
|
| MP1032-CT05 | P2 |
Completed |
COVID-19 |
2022-07-28 |
|
| 2017-003484-36 | P2 |
Completed |
Psoriasis |
2019-06-12 |
|
| MP1032-CT04 | P2 |
Completed |
Psoriasis |
2019-06-12 |